CRL Charles River Laboratories
Permanent stock page ↗Health Care · S&P 500
Next earnings: not announced yet
What 22 analyst firms say about Charles River Laboratories: their latest ratings, price targets and how far the stock is from them. How it works
Analyst window: Latest analyst report within last 1 year
Analyst view · last 1Y
17 rated views · 22 analyst/firm records · 22 firms
Radar score
- S&P 500 · Top Picks · 6MNot scored · Average target is not above the current price
- S&P 500 · Safest consensus · 6MNot scored · Average target is not above the current price
Recent analyst activity · last 90 days
Our tracked history has 18 reports on CRL from 14 analyst firms in the last 90 days (22 firms in the past year).
Comparing each firm's latest target with its previous one: 5 raised their price target, 5 left it unchanged and 3 have their first observed target in the past year.
Ratings, latest available report against the previous one: 1 upgrade and 1 downgrade.
Latest observed target change: Morgan Stanley raised its target from $300.00 (set 7 Aug 2026) to $340.00 on 12 Oct 2026.
Last 1 year. Latest opinion per identifiable analyst within the last 1 year. BUY / HOLD / SELL each count one current analyst vote; unnamed firm records are a fallback.
| Firm | Analyst | Latest rating | Report date | Latest target (USD) |
|---|---|---|---|---|
| Argus | David A Toung | ConflictConflicting reports · excluded | 17 Sep 2026 | 330.00 USD |
| Baird | Eric Coldwell | Buy | 25 Sep 2026 | 334.00 USD |
| Bank of America Securities | Unnamed analyst | Buy | 15 Dec 2025 | 225.00 USD |
| Barclays | Luke Sergott | Buy | 25 Sep 2026 | 330.00 USD |
| Bernstein | Unnamed analyst | — | 1 Jul 2026 | 250.00 USD |
| BNP Paribas Exane | Unnamed analyst | — | 1 Jul 2026 | 250.00 USD |
| Citigroup | Unnamed analyst | Buy | 8 Jul 2026 | 265.00 USD · 16 Jan 2026 |
| CLSA | Michael Luo | Hold | 20 Jul 2026 | 219.00 USD |
| Deutsche Bank | Justin Bowers | Buy | 25 Sep 2026 | 320.00 USD |
| Evercore ISI | Elizabeth Anderson | Buy | 11 Sep 2026 | Conflicting reports · excluded |
| Jefferies | David Windley | Buy | 28 Sep 2026 | 340.00 USD |
| JPMorgan | Casey Woodring | Buy | 6 Aug 2026 | 310.00 USD |
| Mizuho | Ann Hynes | Hold | 25 Sep 2026 | 295.00 USD |
| Morgan Stanley | Ricky Goldwasser | Buy | 12 Oct 2026 | 340.00 USD |
| Piper Sandler | Unnamed analyst | — | 10 Aug 2026 | 300.00 USD |
| RBC Capital Markets | Ryan Halsted | Buy | 25 Sep 2026 | 322.00 USD |
| Redburn | Jamie Clark | Buy | 18 Jun 2026 | 318.00 USD |
| TD Cowen | Charles Rhyee | Buy | 25 Sep 2026 | 325.00 USD |
| UBS | Kevin Caliendo | Buy | 30 Sep 2026 | 357.00 USD |
| Weiss Ratings | Unnamed analyst | — | 28 Sep 2026 | — |
| William Blair | Jared Haase | Buy | 5 Aug 2026 | — |
| Data feed RESEARCH | Research Team | Hold | 2 Nov 2026 | 319.00 USD |
Partial coverage · checked 6 Nov (6 Nov 2026, 02:19 ET). Some research records could not be refreshed. Cached records retained. Prices stream live during the US session; otherwise stored prices delayed about 15 minutes. A summary of analyst opinion, not investment advice.